Sonoma Pharmaceuticals, Inc. (SNOA) has a negative trailing P/E of -1.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 32.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -85.54%, forward earnings yield 3.13%.
Criteria proven by this page:
Overall SharesGrow Score: 50/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -7.3 | 0.76 | 7.30 | 7.90 | - |
| 2017 | 6.5 | 0.07 | 2.83 | 4.72 | - |
| 2018 | -2.3 | -0.08 | 2.18 | 2.00 | - |
| 2019 | -1.3 | 0.02 | 1.46 | 0.81 | - |
| 2020 | -4.4 | 0.05 | 2.57 | 0.81 | - |
| 2021 | -7.5 | -1.35 | 5.53 | 1.59 | - |
| 2022 | -4.2 | 0.22 | 2.45 | 1.68 | - |
| 2023 | -1.3 | 0.06 | 0.83 | 0.50 | - |
| 2024 | -0.6 | 0.01 | 0.45 | 0.22 | - |
| 2025 | -0.8 | 0.02 | 0.62 | 0.19 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-117.81 | $15.08M | $-10.16M | -67.4% |
| 2017 | $-221.70 | $12.83M | $9.27M | 72.3% |
| 2018 | $-284.66 | $16.66M | $-14.33M | -86% |
| 2019 | $-127.68 | $18.97M | $-11.8M | -62.2% |
| 2020 | $-22.40 | $18.94M | $-2.95M | -15.6% |
| 2021 | $-23.65 | $18.63M | $-4.62M | -24.8% |
| 2022 | $-19.17 | $12.63M | $-5.09M | -40.3% |
| 2023 | $-15.18 | $13.27M | $-5.15M | -38.8% |
| 2024 | $-5.32 | $12.74M | $-4.84M | -38% |
| 2025 | $-2.79 | $14.29M | $-3.46M | -24.2% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.61 | $-1.61 – $-1.61 | $20.66M | $20.66M – $20.66M | 1 |
| 2027 | $-0.56 | $-0.56 – $-0.56 | $23.91M | $23.91M – $23.91M | 1 |
| 2028 | $0.07 | $0.07 – $0.07 | $26.95M | $26.95M – $26.95M | 1 |
